KLRS Kalaris Therapeutics, Inc.
Nasdaq · SEC CIK 1754068 · EDGAR
- Bought, last 12 months
- $6.18M 2 purchases by 2 insiders
- Sold, last 12 months
- $12.9K 1 sales by 1 insiders
- Filings on record
- 250 since 2021-09-20, latest 2026-08-28 16:10
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Samsara Opportunity Fund, L.P. | 10% | $5.00M | — |
| AKKARAJU SRINIVAS | Dir, 10% | $1.18M | — |
| Hagen Brett R | CAO | — | $12.9K |
Transactions 221
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-03 | 2022-03-02 | KLRS | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $9.01 | -516 | 382.4K | -0.1% | -$4,649 | |
| 2022-02-18 | 2022-02-16 | KLRS | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $8.32 | -15.3K | 382.9K | -4% | -$127.5K | |
| 2022-02-10 | 2022-02-10 | KLRS | Bornstein Jeffrey S | Dir | P - Purchase | $8.87 | +5,000 | 35.2K | +17% | +$44.3K | |
| 2022-01-26 | 2022-01-25 | KLRS | Atillasoy Ercem | See Remarks | S - Sale | $8.24 | -4,639 | 100.3K | -4% | -$38.2K | |
| 2022-01-25 | 2022-01-24 | KLRS | Hallal David | Dir, 10% | S - Sale | $8.01 | -17.1K | 2.21M | -0.8% | -$137.0K | |
| 2022-01-24 | 2022-01-20 | KLRS | Sinha Vikas | See Remarks, Dir | S - Sale | $8.75 | -6,450 | 859.0K | -0.7% | -$56.4K | |
| 2022-01-24 | 2022-01-20 | KLRS | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $8.75 | -4,656 | 398.2K | -1% | -$40.7K | |
| 2022-01-24 | 2022-01-20 | KLRS | Hagen Brett R | CAO | S - Sale | $8.75 | -1,563 | 63.2K | -2% | -$13.7K | |
| 2021-12-03 | 2021-12-02 | KLRS | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $17.06 | -514 | 402.9K | -0.1% | -$8,769 | |
| 2021-11-18 | 2021-11-16 | KLRS | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $21.13 | -15.2K | 403.4K | -4% | -$321.2K | |
| MI | 2021-11-16 | 2021-11-12+ | KLRS | Leen Ann M. | CSO | S - Sale | $22.18 | -21.0K | 2.29M | -0.9% | -$465.5K |
| MI | 2021-11-15 | 2021-11-10 | KLRS | Jovan-Embiricos Morana | Dir | S - Sale | $24.77 | -800 | 342.7K | -0.2% | -$19.8K |
| MI | 2021-11-09 | 2021-11-05+ | KLRS | Jovan-Embiricos Morana | Dir | S - Sale | $24.80 | -12.2K | 1.38M | -0.9% | -$302.4K |
| MI | 2021-10-29 | 2021-10-27 | KLRS | Jovan-Embiricos Morana | Dir | S - Sale | $24.78 | -2,200 | 1.39M | -0.2% | -$54.5K |
| MI | 2021-10-25 | 2021-10-21+ | KLRS | Jovan-Embiricos Morana | Dir | S - Sale | $24.80 | -13.6K | 1.39M | -1.0% | -$337.1K |
| 2021-10-25 | 2021-10-21 | KLRS | Atillasoy Ercem | See Remarks | S - Sale | $24.23 | -1,514 | 105.0K | -1% | -$36.7K | |
| M | 2021-10-05 | 2021-10-04 | KLRS | Melian Agustin | Chief Medical Off | S - Sale | $23.91 | -18.7K | 456.8K | -4% | -$446.9K |
| M | 2021-10-01 | 2021-09-29+ | KLRS | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $25.14 | -16.6K | 422.0K | -4% | -$416.9K |
| 2021-09-29 | 2021-09-28 | KLRS | Melian Agustin | Chief Medical Off | S - Sale | $24.12 | -3,750 | 472.2K | -0.8% | -$90.5K | |
| M | 2021-09-20 | 2021-04-05+ | KLRS | Melian Agustin | Chief Medical Off | S - Sale | $22.11 | -40.5K | 476.0K | -8% | -$896.7K |
| M | 2021-09-20 | 2021-02-17+ | KLRS | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $26.57 | -53.1K | 490.1K | -10% | -$1.41M |
Purchase Sale Sale after option exercise All abbreviations